论文部分内容阅读
大部分非小细胞肺癌(NSCLC)确诊时已不能手术治愈,不得不依赖化疗改善预后。现所用的抗NSCLC药物仅几种活性超过15％,各种联合方案反应率低于40％。故当务之急是开发新型有效药物。现概述9种新药、新类似物或以新法使用的老药Ⅰ,Ⅱ期试验结果。 CPT-11 是一种有广谱抗癌活性的水溶性喜树碱衍生物,体内可转化为一种有活性的代谢产物SN-38,其细胞毒性主要由该产物引起。日本率先用该药治疗NSCLC。一组 35例病人以 200 mg/m~2· 3～4周治疗,反应率20％,但白细胞减少和腹泻发生率高。另一组72例,剂量100mg/m~2·周,耐受性好,反应率31.9％,25％白细胞减少,21％腹泻。CPT-11+
Most non-small cell lung cancer (NSCLC) diagnosis can no longer be cured, had to rely on chemotherapy to improve the prognosis. Currently used anti-NSCLC drugs only a few activities of more than 15%, various joint program response rate of less than 40%. Therefore, it is imperative to develop new and effective drugs. Now outlines 9 kinds of new drugs, new analogues or new drugs used in the old drug Ⅰ, Ⅱ period test results. CPT-11, a water-soluble camptothecin derivative with a broad spectrum of anticancer activities, is converted in vivo into an active metabolite, SN-38, whose cytotoxicity is predominantly caused by this product. Japan took the lead in the treatment of NSCLC. A group of 35 patients with 200 mg / m ~ 2. 3 to 4 weeks treatment, the response rate of 20%, but the high incidence of leukopenia and diarrhea. Another group of 72 cases, the dose of 100mg / m ~ 2 weeks, well tolerated, the response rate of 31.9%, 25% leukopenia, 21% of diarrhea. CPT-11 +